These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1000 related articles for article (PubMed ID: 22440312)

  • 21. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.
    Thakur A; Kaur H; Kaur S
    Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against Leishmania donovani: a step towards exploring novel vaccine candidate.
    Tandon R; Chandra S; Baharia RK; Misra P; Das S; Rawat K; Siddiqi MI; Sundar S; Dube A
    Parasitology; 2018 Apr; 145(4):508-526. PubMed ID: 28691653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Live Attenuated Leishmania donovani Centrin Knock Out Parasites Generate Non-inferior Protective Immune Response in Aged Mice against Visceral Leishmaniasis.
    Bhattacharya P; Dey R; Dagur PK; Joshi AB; Ismail N; Gannavaram S; Debrabant A; Akue AD; KuKuruga MA; Selvapandiyan A; McCoy JP; Nakhasi HL
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004963. PubMed ID: 27580076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
    Daifalla NS; Bayih AG; Gedamu L
    Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
    Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S
    Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leishmania genome analysis and high-throughput immunological screening identifies tuzin as a novel vaccine candidate against visceral leishmaniasis.
    Lakshmi BS; Wang R; Madhubala R
    Vaccine; 2014 Jun; 32(30):3816-22. PubMed ID: 24814525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leishmania donovani secretory serine protease alters macrophage inflammatory response via COX-2 mediated PGE-2 production.
    Das P; De T; Chakraborti T
    Indian J Biochem Biophys; 2014 Dec; 51(6):542-51. PubMed ID: 25823228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
    Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
    Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
    Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S
    Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.
    Bhowmick S; Mazumdar T; Sinha R; Ali N
    J Control Release; 2010 Jan; 141(2):199-207. PubMed ID: 19818373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LmjMAPK10 offers protection against Leishmania donovani infection.
    Kumar S; Zutshi S; Patidar A; Bodhale N; Roy S; Sarkar A; Saha B
    Parasite Immunol; 2020 Feb; 42(2):e12687. PubMed ID: 31770453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel recombinant Leishmania donovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis.
    Gupta R; Kushawaha PK; Tripathi CD; Sundar S; Dube A
    Int J Parasitol; 2012 May; 42(5):429-35. PubMed ID: 22502587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis.
    Baharia RK; Tandon R; Sharma T; Suthar MK; Das S; Siddiqi MI; Saxena JK; Sundar S; Dube A
    PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003557. PubMed ID: 25745863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IFN-γ
    Yadav S; Prakash J; Singh OP; Gedda MR; Chauhan SB; Sundar S; Dubey VK
    Cell Immunol; 2021 Mar; 361():104272. PubMed ID: 33445051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leishmania donovani: CD2 biased immune response skews the SAG mediated therapy for a predominant Th1 response in experimental infection.
    Bimal S; Sinha S; Singh SK; Narayan S; Kumar V; Verma N; Ranjan A; Sinha PK; Das VN; Pandey K; Kar SK; Das P
    Exp Parasitol; 2012 Jul; 131(3):274-82. PubMed ID: 22580024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cocktail of gp63 and Hsp70 induces protection against Leishmania donovani in BALB/c mice.
    Kaur T; Sobti RC; Kaur S
    Parasite Immunol; 2011 Feb; 33(2):95-103. PubMed ID: 21226722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major.
    Bhaumik S; Basu R; Sen S; Naskar K; Roy S
    Vaccine; 2009 Feb; 27(9):1306-16. PubMed ID: 19162111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-7 potentiates MAPK10-elicited host-protective vaccine against Leishmania donovani.
    Kumar S; Bodhale N; Patra SK; Sarode A; Zhao L; Sarkar A; Saha B
    Cytokine; 2024 Feb; 174():156475. PubMed ID: 38134556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.
    Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E
    Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis.
    Kaye PM; Curry AJ; Blackwell JM
    J Immunol; 1991 Apr; 146(8):2763-70. PubMed ID: 1901883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.